Uncovering Potential Combinations to Weaponize Kinase Inhibitors Against B Cell Malignancies & Autoimmune Disease

Time: 11:30 am
day: Day Two


  • Strategically identifying genes and pathways known to drive the abnormal behaviour of B cells
  • Acquiring and optimizing compounds to develop the best-in-class generation of kinase inhibitors
  • Developing complementary and synergistic drug combinations with TG-1701, umbralisib and ublituximab